<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Annovis Bio Inc — News on 6ix</title>
<link>https://6ix.com/company/annovis-bio-inc</link>
<description>Latest news and press releases for Annovis Bio Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/annovis-bio-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835468878dffbe2df0e305d.webp</url>
<title>Annovis Bio Inc</title>
<link>https://6ix.com/company/annovis-bio-inc</link>
</image>
<item>
<title>Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio</title>
<link>https://6ix.com/company/annovis-bio-inc/news/annovis-publishes-phase-23-alzheimers-trial-results-in-nature-portfolio</link>
<guid isPermaLink="true">https://6ix.com/company/annovis-bio-inc/news/annovis-publishes-phase-23-alzheimers-trial-results-in-nature-portfolio</guid>
<pubDate>Tue, 28 Apr 2026 12:00:00 GMT</pubDate>
<description>Buntanetap improved cognition in pTau217-positive early AD patientsThe drug reduced neurotoxic proteins as well as biomarkers of neuroinflammation and neurodegenerationBuntanetap was safe and well-tolerated, including in ApoE4 carriersPhase 2/3 findings support ongoing pivotal Phase 3 study in early AD, with 80% patients enrolled to date MALVERN, Pa., April 28, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company dev</description>
</item>
<item>
<title>Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission</title>
<link>https://6ix.com/company/annovis-bio-inc/news/annovis-closes-dollar10-million-offering-extending-cash-runway-through-phase-3-alzheimers-disease-6-month-nda-submission</link>
<guid isPermaLink="true">https://6ix.com/company/annovis-bio-inc/news/annovis-closes-dollar10-million-offering-extending-cash-runway-through-phase-3-alzheimers-disease-6-month-nda-submission</guid>
<pubDate>Fri, 10 Apr 2026 12:30:00 GMT</pubDate>
<description>Financing secures path to first NDA submission for buntanetap6-Month symptomatic data readout anticipated Q1 2027Alzheimer’s disease Phase 3 trial 75% enrolledParkinson's disease open-label study 28% enrolled MALVERN, Pa., April 10, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson</description>
</item>
<item>
<title>Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants</title>
<link>https://6ix.com/company/annovis-bio-inc/news/annovis-announces-dollar10-million-underwritten-offering-of-common-stock-and-accompanying-warrants</link>
<guid isPermaLink="true">https://6ix.com/company/annovis-bio-inc/news/annovis-announces-dollar10-million-underwritten-offering-of-common-stock-and-accompanying-warrants</guid>
<pubDate>Thu, 09 Apr 2026 12:30:00 GMT</pubDate>
<description>MALVERN, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the pricing of an underwritten offering of 5,263,156 shares of its common stock, together with accompanying warrants to purchase up to 5,263,156 shares of common stock. The com</description>
</item>
<item>
<title>Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections</title>
<link>https://6ix.com/company/annovis-bio-inc/news/annovis-secures-us-patent-for-buntanetap-in-the-prevention-and-treatment-of-neurological-injuries-caused-by-brain-infections-7</link>
<guid isPermaLink="true">https://6ix.com/company/annovis-bio-inc/news/annovis-secures-us-patent-for-buntanetap-in-the-prevention-and-treatment-of-neurological-injuries-caused-by-brain-infections-7</guid>
<pubDate>Thu, 02 Apr 2026 11:30:00 GMT</pubDate>
<description>MALVERN, Pa., April 02, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the issuance of U.S. Patent No. 12,582,632 B2, covering prevention and treatment of neurological injuries arising from brain infections through the administration of buntanetap</description>
</item>
<item>
<title>Annovis Publishes Historical Review of Buntanetap in The Scientist</title>
<link>https://6ix.com/company/annovis-bio-inc/news/annovis-publishes-historical-review-of-buntanetap-in-the-scientist</link>
<guid isPermaLink="true">https://6ix.com/company/annovis-bio-inc/news/annovis-publishes-historical-review-of-buntanetap-in-the-scientist</guid>
<pubDate>Tue, 31 Mar 2026 12:00:00 GMT</pubDate>
<description>MALVERN, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the publication of an article in The Scientist titled “Buntanetap: From Execution Poison to Potential Alzheimer’s Disease Drug”, examining the history of discovery and developm</description>
</item>
<item>
<title>Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study</title>
<link>https://6ix.com/company/annovis-bio-inc/news/annovis-partners-with-neurorpm-to-deploy-ai-powered-digital-biomarker-technology-in-parkinsons-disease-study</link>
<guid isPermaLink="true">https://6ix.com/company/annovis-bio-inc/news/annovis-partners-with-neurorpm-to-deploy-ai-powered-digital-biomarker-technology-in-parkinsons-disease-study</guid>
<pubDate>Thu, 19 Mar 2026 11:30:00 GMT</pubDate>
<description>MALVERN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced a partnership with NeuroRPM, a digital health technology company, to implement a new FDA-cleared artificial intelligence (AI) platform that collects movement data for symptom a</description>
</item>
<item>
<title>Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results</title>
<link>https://6ix.com/company/annovis-bio-inc/news/annovis-provides-corporate-updates-and-reports-fiscal-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/annovis-bio-inc/news/annovis-provides-corporate-updates-and-reports-fiscal-year-2025-financial-results</guid>
<pubDate>Mon, 16 Mar 2026 11:30:00 GMT</pubDate>
<description>MALVERN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced business updates and reported financial results for the fiscal year 2025. In 2025, Annovis achieved a significant milestone in its clinical development program with the initiat</description>
</item>
<item>
<title>Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference</title>
<link>https://6ix.com/company/annovis-bio-inc/news/annovis-announces-two-presentations-at-the-adpdtm-2026-international-conference</link>
<guid isPermaLink="true">https://6ix.com/company/annovis-bio-inc/news/annovis-announces-two-presentations-at-the-adpdtm-2026-international-conference</guid>
<pubDate>Tue, 03 Mar 2026 13:00:00 GMT</pubDate>
<description>MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced two presentations at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2026), taking place March 17-21, 2026, in Copenhagen, Denmark. The presen</description>
</item>
<item>
<title>Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease</title>
<link>https://6ix.com/company/annovis-bio-inc/news/annovis-secures-dsmb-approval-advance-130000488</link>
<guid isPermaLink="true">https://6ix.com/company/annovis-bio-inc/news/annovis-secures-dsmb-approval-advance-130000488</guid>
<pubDate>Thu, 12 Feb 2026 13:00:00 GMT</pubDate>
<description>MALVERN, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that an independent Data and Safety Monitoring Board (DSMB) has issued a positive recommendation regarding the safety of buntanetap at 6 months, supporting the continuation of t</description>
</item>
<item>
<title>Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients</title>
<link>https://6ix.com/company/annovis-bio-inc/news/annovis-announces-open-label-extension-213500250</link>
<guid isPermaLink="true">https://6ix.com/company/annovis-bio-inc/news/annovis-announces-open-label-extension-213500250</guid>
<pubDate>Thu, 18 Dec 2025 21:35:00 GMT</pubDate>
<description>Enrollment will begin in January 2026 Participants will be treated with buntanetap for 36 months The study aims to enroll 500 patients MALVERN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will begin an Open-Label Extension (OLE) study in January 2026</description>
</item>
<item>
<title>Annovis to Host Corporate Update Webinar on January 28, 2026</title>
<link>https://6ix.com/company/annovis-bio-inc/news/annovis-host-corporate-webinar-january-130000993</link>
<guid isPermaLink="true">https://6ix.com/company/annovis-bio-inc/news/annovis-host-corporate-webinar-january-130000993</guid>
<pubDate>Tue, 16 Dec 2025 13:00:00 GMT</pubDate>
<description>MALVERN, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will host a corporate update webinar followed by a live Q&A session. The webinar will feature Maria Maccecchini, Ph.D., President and CEO, who will provide an overview of the Company’s recent progre</description>
</item>
<item>
<title>Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group</title>
<link>https://6ix.com/company/annovis-bio-inc/news/annovis-present-2025-annual-meeting-130000332</link>
<guid isPermaLink="true">https://6ix.com/company/annovis-bio-inc/news/annovis-present-2025-annual-meeting-130000332</guid>
<pubDate>Wed, 03 Dec 2025 13:00:00 GMT</pubDate>
<description>MALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will present at the 2025 Annual Meeting of the Parkinson Study Group (PSG), taking place December 4-6, 2025 in San Diego, California. The presentation builds on momentum from the Company’s recent Ph</description>
</item>
<item>
<title>Annovis Announces Two Presentations at the CTAD 2025 Conference</title>
<link>https://6ix.com/company/annovis-bio-inc/news/annovis-announces-two-presentations-ctad-130000938</link>
<guid isPermaLink="true">https://6ix.com/company/annovis-bio-inc/news/annovis-announces-two-presentations-ctad-130000938</guid>
<pubDate>Mon, 24 Nov 2025 13:00:00 GMT</pubDate>
<description>MALVERN, Pa., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced two presentations at the 18th Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place December 1-4, 2025 in San Diego, California. The presentations will highlight progress across the Al</description>
</item>
<item>
<title>Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study</title>
<link>https://6ix.com/company/annovis-bio-inc/news/annovis-announces-fda-meeting-discuss-130000974</link>
<guid isPermaLink="true">https://6ix.com/company/annovis-bio-inc/news/annovis-announces-fda-meeting-discuss-130000974</guid>
<pubDate>Tue, 18 Nov 2025 13:00:00 GMT</pubDate>
<description>MALVERN, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that the U.S. Food and Drug Administration (FDA) has scheduled a Type C meeting in January 2026 to discuss the Company's pathway for Parkinson's disease dementia (PDD). Annovis also reaffirmed that its</description>
</item>
<item>
<title>Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients</title>
<link>https://6ix.com/company/annovis-bio-inc/news/annovis-reports-biomarker-data-linking-130000626</link>
<guid isPermaLink="true">https://6ix.com/company/annovis-bio-inc/news/annovis-reports-biomarker-data-linking-130000626</guid>
<pubDate>Mon, 17 Nov 2025 13:00:00 GMT</pubDate>
<description>Buntanetap significantly improves cognition in all Parkinson’s patients, with those exhibiting Alzheimer’s co-pathology showing a three-times greater response New data demonstrate reductions in plasma biomarkers pTau217, total tau, and brain-derived tau following buntanetap treatment Findings support buntanetap's potential to address cognitive decline in Parkinson's disease, show disease-modifying efficacy, and inform future clinical development MALVERN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- An</description>
</item>
<item>
<title>Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/annovis-bio-inc/news/annovis-provides-corporate-updates-reports-130000560</link>
<guid isPermaLink="true">https://6ix.com/company/annovis-bio-inc/news/annovis-provides-corporate-updates-reports-130000560</guid>
<pubDate>Wed, 12 Nov 2025 13:00:00 GMT</pubDate>
<description>MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and third quarter 2025 financial results. "The past quarter delivered breakthrough progress on every front," said Maria Maccecchini, Ph.D., President and CEO of Annovis. "Our pivotal P</description>
</item>
<item>
<title>Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program</title>
<link>https://6ix.com/company/annovis-bio-inc/news/annovis-achieves-significant-milestones-sustains-130000770</link>
<guid isPermaLink="true">https://6ix.com/company/annovis-bio-inc/news/annovis-achieves-significant-milestones-sustains-130000770</guid>
<pubDate>Thu, 06 Nov 2025 13:00:00 GMT</pubDate>
<description>All 84 clinical sites across the U.S. are fully activated, enrolling, and treating patients The first group of participants reached the 6-month treatment milestone The study is now 25% complete, keeping Annovis on track for data readout MALVERN, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkin</description>
</item>
<item>
<title>Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules</title>
<link>https://6ix.com/company/annovis-bio-inc/news/annovis-announces-3-4-million-120000709</link>
<guid isPermaLink="true">https://6ix.com/company/annovis-bio-inc/news/annovis-announces-3-4-million-120000709</guid>
<pubDate>Mon, 27 Oct 2025 12:00:00 GMT</pubDate>
<description>MALVERN, Pa., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that it has entered into definitive agreements, with the participation of Michael Hoffman, the Chairman of the Company’s board of directors, and Dr. Maria Maccecchini, the Company’s Chief Executive Off</description>
</item>
<item>
<title>Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock</title>
<link>https://6ix.com/company/annovis-bio-inc/news/annovis-announces-closing-6-million-211500839</link>
<guid isPermaLink="true">https://6ix.com/company/annovis-bio-inc/news/annovis-announces-closing-6-million-211500839</guid>
<pubDate>Wed, 15 Oct 2025 21:15:00 GMT</pubDate>
<description>MALVERN, Pa., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the closing of its previously announced registered direct offering for the purchase of an aggregate of 4,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price</description>
</item>
<item>
<title>Annovis Announces $6 Million Registered Direct Offering of Common Stock</title>
<link>https://6ix.com/company/annovis-bio-inc/news/annovis-announces-6-million-registered-123100974</link>
<guid isPermaLink="true">https://6ix.com/company/annovis-bio-inc/news/annovis-announces-6-million-registered-123100974</guid>
<pubDate>Fri, 10 Oct 2025 12:31:00 GMT</pubDate>
<description>MALVERN, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that it has entered into definitive agreements for the purchase of an aggregate of 4,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.50 per share (</description>
</item>
</channel>
</rss>